EBITDA Margin % is calculated as EBITDA divided by its Revenue. Prime Medicine's EBITDA for the
three
months ended in Mar. 2024 was $-47.03 Mil. Prime Medicine's Revenue for the
three
months ended in Mar. 2024 was $0.59 Mil. Therefore, Prime Medicine's EBITDA margin for the quarter that ended in Mar. 2024 was -7,957.02%.
Prime Medicine EBITDA Margin % Historical Data
The historical data trend for Prime Medicine's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Prime Medicine's EBITDA Margin %
For the Biotechnology subindustry, Prime Medicine's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Prime Medicine's EBITDA Margin % falls into.
Prime Medicine EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Prime Medicine's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (NAS:PRME) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Prime Medicine EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Prime Medicine's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Prime Medicine (Prime Medicine) Business Description
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRME has been successfully added to your 